Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pien Tze Huang for prevention and treatment of radiotherapy-induced oral mucositis in head and neck cancer
ChiCTR2200061657Phase 4Not yet recruiting
- Sponsor
- The Second People's Hospital Affiliated to Fujian University of Chinese Medicine
- Start
- Mar 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Pien Tze Huang in stomatitis and head and neck cancer (HNC) (2 arms), sponsored by The Second People's Hospital Affiliated to Fujian University of Chinese Medicine. Primary endpoints: Incidence of oral mucositis at all grades and Adverse events. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
Pien Tze Huang
03
Conditions
stomatitishead and neck cancer (HNC)
Beyond the preview
Go deeper on ChiCTR2200061657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061657.